PMID- 38001323
OWN - NLM
STAT- MEDLINE
DCOM- 20240404
LR  - 20240404
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Linking)
VI  - 84
IP  - 1
DP  - 2024 Apr
TI  - Efficacy of fecal microbiota transplantation in type 2 diabetes mellitus: a 
      systematic review and meta-analysis.
PG  - 48-62
LID - 10.1007/s12020-023-03606-1 [doi]
AB  - OBJECTIVE: Type 2 diabetes mellitus (T2DM) is one of the common metabolic 
      diseases worldwide, and studies have found significant differences in the 
      composition and ratio of intestinal flora between patients with T2DM and normal 
      glucose tolerance, and fecal microbiota transplantation (FMT) may modulate the 
      composition of the intestinal microbiota thereby alleviating the hyperglycemic 
      state. We conducted a meta-analysis and systematic review of existing randomized 
      controlled trials (RCTs) to assess the efficacy of FMT in T2DM. METHODS: We 
      conducted a computer search of PubMed, Embase, The Cochrane Library, and Web of 
      Science to screen randomized controlled trials studies on FMT treatment for T2DM 
      and extracted data from studies that met inclusion criteria. RevMan 5.4 software 
      and Stata 11 software was used for meta-analysis. The indexes of Hemoglobin A1c 
      (HbA1c), fasting plasma glucose (FPG), postprandial blood glucose (PBG), 
      homeostasis model assessment of insulin resistance (HOMA-IR), triglycerides (TG), 
      cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), 
      body mass index (BMI), Aspartate Aminotransferase (AST), Alanine Transaminase 
      (ALT), Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) were 
      mainly evaluated after FMT treatment of T2DM patients, and the changes of 
      intestinal flora were evaluated. RESULTS: Four RCTs met the inclusion criteria 
      and were included in the meta-analysis. Results of the meta-analysis showed that 
      compared with the non-FMT group, FMT combined treatment could significantly 
      reduce the PBG level in patients with type 2 diabetes (MD = -0.51, 95% CI: 
      -1.42-0.40, P = 0.27). Compared with single FMT treatment, FMT combined treatment 
      could reduce TG levels in patients with type 2 diabetes (MD = -0.60, 95% CI: 
      -1.12~-0.07, P = 0.03). The levels of TG (MD = -0.26, 95% CI: -0.51~-0.02, 
      P = 0.03), HOMA-IR (MD = -2.73, 95% CI: -4.71~0.75, P = 0.007) and HDL 
      (MD = -0.06,95% CI: -0.10~-0.02, P = 0.003) were significantly decreased after 
      treatment in the single FMT group. The level of TC (MD = -0.65, 95% CI: 
      -1.00~-0.31, P = 0.0002) was significantly decreased after FMT combined 
      treatment. Compared with before treatment, ALT (MD = -2.52, 95% CI: -3.86~-1.17, 
      P = 0.0002) and DBP (MD = -2, 95% CI: -3.32~0.68, P = 0.003) levels decreased 
      after treatment in the single FMT group and the FMT combined group. FPG 
      (MD = -0.94, 95% CI: -1.86~-0.02, P = 0.04), TG (MD = -0.73, 95% CI: -1.42~-0.04, 
      P = 0.04) and TC (MD = -0.94, 95% CI: -1.45~-0.43, P = 0.0003) were significantly 
      decreased after combined drug and diet therapy. Secondly, FMT can promote the 
      colonization and growth of donor-related flora in patients with type 2 diabetes. 
      CONCLUSION: In patients with type 2 diabetes mellitus, FMT treatment can reduce 
      the levels of PBG, TG, HOMA-IR, TC, ALT, and DBP, especially in the combined 
      treatment regimen. In addition, FMT can reshape the intestinal flora and 
      establish the balance of dominant flora.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Yang, Yan
AU  - Yang Y
AD  - Clinical Medical College of Hebei University of Engineering, Handan, Hebei, 
      056000, China.
FAU - Yan, Jingjing
AU  - Yan J
AD  - Clinical Medical College of Hebei University of Engineering, Handan, Hebei, 
      056000, China.
FAU - Li, Shuo
AU  - Li S
AD  - Clinical Medical College of Hebei University of Engineering, Handan, Hebei, 
      056000, China.
FAU - Liu, Mengru
AU  - Liu M
AD  - Clinical Medical College of Hebei University of Engineering, Handan, Hebei, 
      056000, China.
FAU - Han, Ruimin
AU  - Han R
AD  - Clinical Medical College of Hebei University of Engineering, Handan, Hebei, 
      056000, China.
FAU - Wang, Yinping
AU  - Wang Y
AD  - Clinical Medical College of Hebei University of Engineering, Handan, Hebei, 
      056000, China.
FAU - Wang, Zhen
AU  - Wang Z
AD  - Clinical Medical College of Hebei University of Engineering, Handan, Hebei, 
      056000, China. wangzhen@hebeu.edu.cn.
FAU - Wang, Defeng
AU  - Wang D
AD  - Endocrinology Department of Affiliated Hospital of Hebei University of 
      Engineering, Handan, Hebei, 056000, China. wdf991217@126.com.
LA  - eng
GR  - (No.[2020] No.23)/Project Fund of Clinical Medicine Excellent Talents funded by 
      Hebei Provincial Department of Finance (No.: [2020] No.23);/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20231125
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
RN  - 0 (Triglycerides)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Blood Glucose)
SB  - IM
MH  - Humans
MH  - *Fecal Microbiota Transplantation
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Triglycerides
MH  - Cholesterol
MH  - Body Mass Index
MH  - Lipoproteins, HDL
MH  - Blood Glucose/metabolism
OTO - NOTNLM
OT  - Fecal microbiota transplantation (FMT)
OT  - Gut microbiota
OT  - Meta-analysis
OT  - Type 2 diabetes mellitus
EDAT- 2023/11/25 07:43
MHDA- 2024/04/04 06:45
CRDT- 2023/11/24 23:39
PHST- 2023/05/28 00:00 [received]
PHST- 2023/10/29 00:00 [accepted]
PHST- 2024/04/04 06:45 [medline]
PHST- 2023/11/25 07:43 [pubmed]
PHST- 2023/11/24 23:39 [entrez]
AID - 10.1007/s12020-023-03606-1 [pii]
AID - 10.1007/s12020-023-03606-1 [doi]
PST - ppublish
SO  - Endocrine. 2024 Apr;84(1):48-62. doi: 10.1007/s12020-023-03606-1. Epub 2023 Nov 
      25.